Fred Alger Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$219K Sell
283
-135
-32% -$103K ﹤0.01% 421
2025
Q4
$323K Sell
418
-95
-19% -$64.5K ﹤0.01% 419
2025
Q3
$288K Buy
513
+32
+7% +$18.1K ﹤0.01% 425
2025
Q2
$253K Buy
481
+104
+28% +$58K ﹤0.01% 411
2025
Q1
$239K Buy
+377
New +$259K ﹤0.01% 407
2024
Q4
Sell
-8,821
Closed -$9.27M 460
2024
Q3
$9.27M Sell
8,821
-2,302
-21% -$2.56M 0.04% 188
2024
Q2
$11.7M Sell
11,123
-36,878
-77% -$35.7M 0.06% 173
2024
Q1
$46.2M Sell
48,001
-2,596
-5% -$2.47M 0.23% 86
2023
Q4
$44.4M Sell
50,597
-12,323
-20% -$10.1M 0.24% 87
2023
Q3
$51.8M Buy
62,920
+62,836
+74,805% +$49.4M 0.3% 87
2023
Q2
$60.4K Sell
84
-62,665
-100% -$48.3M ﹤0.01% 456
2023
Q1
$51.6M Buy
62,749
+33,359
+114% +$25.2M 0.28% 111
2022
Q4
$21.2M Buy
29,390
+16,831
+134% +$12.4M 0.11% 164
2022
Q3
$8.65M Buy
+12,559
New +$7.9M 0.04% 216
2020
Q4
Sell
-10,557
Closed -$5.91M 497
2020
Q3
$5.91M Sell
10,557
-1,500
-12% -$910K 0.02% 233
2020
Q2
$7.52M Buy
12,057
+1,242
+11% +$705K 0.02% 201
2020
Q1
$5.28M Buy
+10,815
New +$4.46M 0.02% 211
2019
Q3
Sell
-31
Closed -$10K 533
2019
Q2
$10K Sell
31
-80,712
-100% -$26.9M ﹤0.01% 492
2019
Q1
$33.2M Buy
+80,743
New +$33.2M 0.13% 142
2018
Q3
Sell
-1,000
Closed -$345K 574
2018
Q2
$345K Buy
+1,000
New +$313K ﹤0.01% 373
2017
Q4
Sell
-4,000
Closed -$1.79M 585
2017
Q3
$1.79M Sell
4,000
-2,000
-33% -$952K 0.01% 287
2017
Q2
$2.95M Buy
+6,000
New +$2.63M 0.01% 259
2016
Q1
Sell
-62,962
Closed -$34.2M 596
2015
Q4
$34.2M Sell
62,962
-2,117
-3% -$1.15M 0.17% 98
2015
Q3
$30.3M Buy
65,079
+54,979
+544% +$29.5M 0.17% 106
2015
Q2
$5.15M Buy
+10,100
New +$4.93M 0.02% 301
2013
Q4
Sell
-59,108
Closed -$18.5M 595
2013
Q3
$18.5M Buy
59,108
+10,519
+22% +$2.77M 0.1% 212
2013
Q2
$10.9M Buy
+48,589
New +$11.3M 0.06% 279

Other funds holding REGN

Fred Alger Management's REGN Position: Q1 2026 in Review

Fred Alger Management reduced its Regeneron Pharmaceuticals (REGN) stake by 32% in Q1 2026, selling an estimated $103K and leaving 283 shares worth $219K. The position accounts for ﹤0.01% of the portfolio, ranked #421.

Fred Alger Management first reported a position in REGN in Q2 2013 and has held it in 27 quarters since. The position peaked at $51.8M in Q3 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Fred Alger Management held 283 shares of Regeneron Pharmaceuticals worth $219K as of Q1 2026.
  • Fred Alger Management sold 135 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $103K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Fred Alger Management's portfolio in Q1 2026, its #421 holding.
  • Fred Alger Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 27 quarters since.
  • Fred Alger Management's Regeneron Pharmaceuticals position peaked at $51.8M in Q3 2023.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Fred Alger Management's 13F filing for Q1 2026, filed 15 May 2026.